Quantcast

Researcher ID new target for anti-HIV drugs

Researchers say they have discovered a new target on the HIV molecule that could potentially lead to a new class of anti-viral drugs to fight the virus that causes AIDS. “The greatest challenge in treating HIV today is drug resistance brought on when the virus mutates and renders existing drugs ineffective at stopping viral replication,” said a lead researcher. “Our research has led to the identification of a new class of compounds that inhibit a novel target in HIV. These compounds disrupt the assembly of the HIV-1 capsid protein, which is a vital step in changing immature, non-infectious HIV into its mature, infectious form.”

Human sperm may 'smell' their way to the egg

A better understanding of the new “smelling” capabilities of human sperm cells may lead to advances in contraception and fertility treatments. A new study identifies a novel odorant receptor on human sperm and shows how activating this receptor causes the sperm to make a beeline for a target. In a study appearing in the 28 March issue of the journal, Science, German and U.S. researchers report that the binding of certain compounds to the new odorant receptor (hOR17-4) found on the surface of sperm cells, triggers a series of physiological events that may result in the directed movement of human sperm. In this chemosensory response, the sperm cells travel toward elevated concentrations of a sperm-attracting substance called “bourgeonal.”

Navy wants ‘affordable’ weapons for war on terrorism

Cruise missiles have proven themselves in combat many times since the Gulf War, but the Navy would like to drive their cost down–the ones currently in service cost hundreds of thousands of dollars. The Office of Naval Research (ONR) has a program to use commercially-based equipment to build a “cruise-like” missile with good performance at a price ten times less than the norm. The new missile is called, appropriately, the Affordable Weapon.

Melanoma discovery could aid diagnosis, treatment

Scientists at Emory University School of Medicine have identified a signaling pathway that is turned on when benign moles turn into early-stage malignant melanoma. The pathway could provide a new target for the diagnosis, prevention and treatment of the most lethal form of skin cancer. The research was reported in the December issue of the journal Clinical Cancer Research.